Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.7
27.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Kiniksa Pharmaceuticals Ltd
Wall Street
Price Targets
KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
KNSA
is 36.72 USD
with a low forecast of 32.32 USD and a high forecast of 42 USD.
KNSA Last Price Targets
Kiniksa Pharmaceuticals Ltd
The latest public price target was made on Oct 29, 2024 by
Liisa Bayko
from
Evercore ISI
,
who expects
KNSA
stock to
rise by 66%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Liisa Bayko
Evercore ISI
|
35
USD
Upside 66% |
3 weeks ago
Oct 29, 2024
|
Kiniksa (KNSA) PT Raised to $35 at Evercore ISI
StreetInsider
|
Roger Song
Jefferies
|
40
USD
Upside 90% |
2 months ago
Sep 13, 2024
|
Jefferies Starts Kiniksa (KNSA) at Buy
StreetInsider
|
Eva Fortea Verdejo
Wells Fargo
|
34
USD
Upside 61% |
6 months ago
May 3, 2024
|
Wells Fargo Starts Kiniksa (KNSA) at Overweight, 'we see +15-25% upside potential'
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is KNSA's stock price target?
Price Target
36.72
USD
According to Wall Street analysts, the average 1-year price target for
KNSA
is 36.72 USD
with a low forecast of 32.32 USD and a high forecast of 42 USD.
What is Kiniksa Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
37%
The
compound annual growth rate
of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is
37%.
What is Kiniksa Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
56%
The
compound annual growth rate
of Kiniksa Pharmaceuticals Ltd's net income for the next 3 years is
56%.
You don't have any saved screeners yet
